Skip to content

Decipher Prostate Biopsy Genomic Classifier

The Decipher Prostate Biopsy Genomic Classifier test report overview can help you understand components of the test report.

Home > Decipher Prostate > Physicians > Biopsy Test Report Guide

Page 1 contains the Decipher Score, risk estimates, and an interpretation of the score.

1

1. Decipher Score

  • Determined by tumor biology alone, not influenced by clinicopathologic risk factors (e.g., Gleason, PSA)
  • 22 genes, 7 biological pathways
  • Continuous genomic risk score
  • 3 categories (low, intermediate, high)
2

2. Risk Estimates

  • Prostate cancer risk estimates were determined by numerical integration of >22,000 prostate cancer patients with available Decipher scores calibrated to >40,000 patients with long-term follow-up from published meta-analyses. 

  • Risk of 5- & 10-year metastasis and 15-year prostate cancer mortality with definitive treatment relevant to this patient’s clinical risk group
  • Adverse pathology at time of RP: Grade Group 3-5, pT3b-T4, or lymph node involvement
3

3. Interpretation

Summary based on the patient’s genomic risk & relevant clinical findings

Page 2 contains case analysis, interpretation, and clinical findings.

4

4. Dynamic Report

The report is tailored to the clinical presentation of the patient

5

5. Interpretation

  • This patient’s 10-year risk of metastasis is compared to 6,299 patients with similar clinical features
  • For these patients, Decipher risk groups are distributed as:
    • 61% Low
    • 18% Intermediate
    • 21% High
  • Distribution of risk is dependent on clinical risk group
6

6. Risk Comparisons

  • Explains risk comparison graphic
  • Specifies this patient’s percentile of risk relative to patients with similar clinical features
7

7. Clinical Findings

Clinical study results relevant to this patient

Page 3 contains a test description, intended use info, confidence intervals, and references.

8

8. Test Description

  • How the test is performed
  • Definitions for each of the endpoints reported
  • Provides detail on the cut-points for Decipher risk groups
9

9. Intended Use

Decipher Prostate Biopsy is intended for use in men with localized prostate cancer after surgery with undetectable, persistent, or rising PSA

10

10. Confidence Intervals

The 95% confidence interval for each endpoint reported

11

11. References

For reach of the clinical studies cited in the report